![]() ![]() Schwartz has authored nearly 200 papers and 17 book chapters. Schwartz has worked on a number of review committees for the National Institutes of Health and has served on the editorial boards of various scientific journals, including the Journal of Clinical Oncology and Clinical Cancer Research, of which he is currently an associate editor. Many drugs that originated in his lab are now being evaluated in clinical trials.ĭr. ![]() His laboratory programs have been supported by the National Cancer Institute with R01 and Sarcoma SPORE grants. His studies are aimed at understanding the mechanisms underlying cell cycle and cell death, in order to improve the effectiveness of currently available treatments. At Memorial Sloan-Kettering, he also directed the Laboratory of New Drug Development, leading and supporting laboratory research in anticancer therapies ranging from fundamental basic research, to novel phase I clinical trials, to molecularly targeted treatments of organ-specific cancers. Schwartz joins NewYork-Presbyterian/Columbia from Memorial Sloan-Kettering Cancer Center, where he was chief of the melanoma and sarcoma service. ![]() “Further, he brings a keen sense of compassion and commitment to patient-centered practice, personifying all that we strive for in clinical care at NewYork-Presbyterian/Columbia.”ĭr. Landry, physician-in-chief at NewYork-Presbyterian/Columbia and the Samuel Bard Professor of Medicine and chair of the Department of Medicine at Columbia University Medical Center. Schwartz’s expertise, not only in the treatment of melanoma, sarcoma, and cancers of the gastrointestinal tract, but also a wide variety of solid tumors and hematologic malignancies, through his focus on novel agents with activity against fundamental mechanisms of cancer,” said Dr. Schwartz will be an invaluable asset in our research efforts, from the molecular and cellular mechanisms of cancer, through its unique behavior in different tissues, to statistical aspects of its occurrence and treatment in large populations.” “He brings an unparalleled background in translational and clinical research, including the development and testing of new anticancer drugs. Stephen Emerson, director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia and the Clyde and Helen Wu Professor of Immunology (in Medicine) and professor of microbiology and immunology at Columbia University Medical Center. He also will continue his research on improving ways to treat melanoma, sarcoma, and cancers of the gastrointestinal tract, his areas of expertise and clinical specialty. Schwartz will lead the expansion of clinical research and patient care, with a focus on building a comprehensive team of physicians and scientists to conduct research on the full spectrum of cancers and to bring the resulting advances to patients. He assumed his new role on January 1, 2014.Īt the Herbert Irving Comprehensive Cancer Center, Dr. Gary Schwartz chief of the Division of Hematology/Oncology in the Department of Medicine and associate director for research of its Herbert Irving Comprehensive Cancer Center. NEW YORK, NY - NewYork-Presbyterian/Columbia University Medical Center has named leading physician-scientist Dr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |